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In Brief
Chun et al. perform integrated molecular
analyses of extra-cranial malignant
rhabdoid tumors (MRTs) and show that,
although SMARCB1 loss drives nearly all
MRTs, there are two subgroups of MRTs
that are associated with patient age and
differentially expressed genes.
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http://dx.doi.org/10.1016/j.ccell.2016.02.009SUMMARYMalignant rhabdoid tumors (MRTs) are rare lethal tumors of childhood that most commonly occur in the kid-
ney and brain. MRTs are driven by SMARCB1 loss, but the molecular consequences of SMARCB1 loss
in extra-cranial tumors have not been comprehensively described and genomic resources for analyses of
extra-cranial MRT are limited. To provide such data, we used whole-genome sequencing, whole-genome
bisulfite sequencing, whole transcriptome (RNA-seq) and microRNA sequencing (miRNA-seq), and histone
modification profiling to characterize extra-cranial MRTs. Our analyses revealed gene expression and
methylation subgroups and focused on dysregulated pathways, including those involved in neural crest
development.INTRODUCTION
Malignant rhabdoid tumors (MRTs) are aggressive pediatric
solid tumors with a median age at diagnosis of 11 months
(Weeks et al., 1989). MRTs may originate from cells in the neu-
ral crest lineage (Blatt et al., 1986; Fischer et al., 1989; Ota
et al., 1993; Sugimoto et al., 1999) and can occur throughout
the body, but they are detected frequently in kidneys (rhabdoid
tumors of the kidney [RTK]) and brain (atypical teratoid/rhab-
doid tumors [AT/RT]). Although considered rare (Brennan
et al., 2013), the clinical burden of MRTs is considerable, with
extra-cranial MRTs in infants accounting for 18% of renalSignificance
To facilitate comparisons between cranial and extra-crania
SMARCB1 loss, we performed comprehensive genomic ana
almost uniformly driven by SMARCB1 loss, we observed mole
subgroups associated with patient age, and differentially exp
developmental pathways were observed in gene expression s
crest development. We present evidence for altered epigene
hancers and dysregulation of homeobox genes.
394 Cancer Cell 29, 394–406, March 14, 2016 ª2016 Elsevier Inc.tumors, 14% of soft tissue tumors, and 9% of liver tumors
(Brennan et al., 2013). Overall 4-year survival is only 23.2%
(Tomlinson, 2005) and thus more effective treatment options
are needed.
SMARCB1 loss drives MRTs (Biegel et al., 2002; Versteege
et al., 1998). In rare cases, SMARCA4 loss is the driver (Schnep-
penheim et al., 2010). Whole-genome sequence analysis of MRT
has not been reported, but previous exome (Lee et al., 2012) and
SNP array studies (Hasselblatt et al., 2013; Jackson et al., 2009;
McKenna et al., 2008) noted a paucity of somatic mutations in
MRT genomes, compatible with the notion thatMRT progression
is driven predominantly by SMARCB1 loss. Despite this nearlyl MRTs and to study the genome-wide consequences of
lyses of pediatric extra-cranial MRT cases. Despite being
cular heterogeneity within extra-cranial MRTs. Methylation
ressed members of the EMT-, BMP-, and WNT-mediated
ubgroups, as was dysregulation of genes involved in neural
tic states, noting the existence of MRT-specific super-en-
Figure 1. Mutations Identified in 40 MRT
Cases
The figure shows selected alterations detected
usinggenomeanalysis (top;CNNLOH, copy number
neutral LOH), the numberand typesof somaticSNVs
(middle; median of 612.5mutations is indicated by a
dashed line), and clinical characteristics of 40 MRT
cases (bottom). Each column represents a sample.
See also Figure S1 and Tables S1 and S2.ubiquitous driver event, studies have alluded to clinical hetero-
geneity in MRTs, as there are a few long-term survivors (Ammer-
laan et al., 2008; Hirth et al., 2003; Ravindra et al., 2002), and
correlations of patient outcome with age at diagnosis and with
tumor stage have been reported (Tekautz et al., 2005; Tomlin-
son, 2005).
SMARCB1 and SMARCA4 are core subunits of the chro-
matin-remodeling SWItch/Sucrose Non-Fermentable (SWI/
SNF) complex, a highly conserved global transcription regulator
that can recruit transcription factors to target genes (Kia et al.,
2008) or modulate target gene expression by altering nucleo-
some position (Tolstorukov et al., 2013). Loss of SMARCB1
has been reported in other neoplasms such as epithelioid sar-
comas (Sullivan et al., 2013) and schwannomatosis (Hadfield
et al., 2008). Previous studies of MRT samples and cell lines
described the consequences of SMARCB1 loss, which
included dysregulated G0-G1 cell cycle transition (Betz et al.,
2002; Zhang et al., 2002); aberrant activation of the sonic
hedgehog (Jagani et al., 2010) and WNT/b-catenin signaling
pathways (Mora-Blanco et al., 2014); and dysregulated expres-
sion of genes involved in embryonic stem cell self-renewal (Wil-
son et al., 2010) and neural or neural crest development (Gadd
et al., 2010).
MRT molecular heterogeneity has also been reported. Torchia
et al. (2015) reported two gene expression subgroups within
AT/RT and correlation of these with survival characteristics.
However, the existence of molecularly distinguishable sub-
groups has not been described in extra-cranial MRTs, and the
extent to which the molecular signatures of AT/RT and extra-
cranial MRT overlap is not fully understood, with inconsistent
reports in the literature (Grupenmacher et al., 2013; Pomeroy
et al., 2002).
As part of the Therapeutically Applicable Research To
Generate Effective Treatments (TARGET) initiative (http://ocg.
cancer.gov/programs/target), we aimed to provide comprehen-
sive molecular profiles and integrative analyses of extra-cranial
MRTs.Cancer Cell 29, 394–40RESULTS
To facilitate comparisons across the
spectrum of MRTs, we applied whole
genome sequencing, whole transcriptome
(RNA-seq) and microRNA sequencing
(miRNA-seq), chromatin immunoprecipi-
tation sequencing (ChIP-seq) for histone
modification profiling, and genome-wide
DNAmethylation analyses (e.g., Roadmap
Epigenomics Consortium, 2015) to extra-cranial MRT cases, MRT cell lines (G401, KP-MRT-RY, KP-
MRT-NS), and human embryonic stem cell (hESC) lines (H7,
H9, H14; Table S1).
MRT Whole-Genome Sequence Landscape
We produced whole-genome sequence landscapes for 40 MRT
cases (Table S1), analyzing sequence data from pairs of tumor
andmatched normal samples to reveal single nucleotide variants
(SNVs), insertion and deletion mutations (InDels), and structural
alterations, e.g., copy number alterations (CNAs) and loss of het-
erozygosity (LOH). Our analyses confirmed inactivating muta-
tions, copy number losses, or somatic LOH affecting SMARCB1
in 39 of 40 cases. The single case lacking a SMARCB1 alteration
harbored somatic LOH and a germline deletion of one base in
SMARCA4 (Figure 1).
As expected (Lawrence et al., 2013; Lee et al., 2012), somatic
SNV rates in MRTs were low (median of 612.5 per case, 0.231
mutations/Mb; Figure 1) with 97.1% of mutations in non-coding
regions. We observed a correlation between age at diagnosis
and mutation rate (Figure S1A). Case PADYZI exhibited an
increased proportion of T>G transversions (Figures 1 and S1B)
and, together with case PAUEKW, had the highest number of so-
matic mutations (Figures 1 and S1C). Mutations in DNA repair
genes were not observed in either case. The PADYZI mutation
spectrum was most strongly correlated to signatures 9 and 17
from Alexandrov et al. (2013), characterized by T>G mutations
(Pearson correlation coefficients = 0.607 and 0.962, respec-
tively). The mutation spectrum of PAUEKW was most strongly
correlated with signatures 1A and 1B (Pearson correlation
coefficients = 0.877 and 0.925, respectively), characterized by
C>T mutations in the context of NpCpG trinucleotides that are
presumed to arise from spontaneous deamination of 5-methyl-
cytosine (Alexandrov et al., 2013).
We observed a total of 204 non-synonymous (NS) amino acid
substitutions (median, 5 per case; range, 1–17). Besides
SMARCB1, DSCAM was the only recurrent target of somatic
NS alteration, with two cases exhibiting heterozygous somatic6, March 14, 2016 ª2016 Elsevier Inc. 395
NS substitutions (p.Val424Ile and p.Ser1354Thr; Figure 1). While
DSCAM alterations may be passenger mutations, somatic
DSCAM alterations were detected at frequencies of 10% or
more in prostate, uterine, colorectal, and lung cancers in
the Cancer Genome Atlas (TCGA) datasets as reported via
cBioPortal (Cerami et al., 2012; Gao et al., 2013).
We extended our analysis to introns and regions 2 kb
upstream of transcriptional start sites, looking for recurrent so-
matically mutated genes associated with dysregulated gene
expression. We identified SPECC1L intron mutations in six
cases and KCNJ3 intron mutations in eight cases (Figures S1D
and S1E). The difference in mean gene expression values be-
tween cases with mutations in these genes and non-mutated
cases was significant (Benjamini Hochberg [BH]-corrected
Wilcoxon p = 1.82 3 1010 and 2.30 3 1008 for SPECC1L
and KCNJ3, respectively), with SPECC1L mutations associated
with decreased SPECC1L expression (log2 fold change [FC] =
1.45; Figure S1F) and KCNJ3 mutations associated with
increased KCNJ3 expression (log2FC = 1.20; Figure S1G).
Eleven lociwere affectedby recurrent somatic copynumberde-
letions, and four lociwere affectedby recurrent somatic gains (Fig-
ure S1H). Nine of 15 loci with CNA were on chromosome 22, on
which SMARCB1 resides (Figure S1I). Genes within gains did not
exhibit significant expression increases, but 115 genes within de-
letions exhibited significant expression decreases compared with
cases without copy number deletions (BH-adjusted Wilcoxon
p < 0.05; Table S2). All but two chromosome 22 deletions involved
SMARCB1 (Figure 1), and thesewere focal deletions affectingNF2
and LIF. Regions 5q34 (five cases); 5q31.3-5q32 (two cases), and
7q35 (two cases) exhibited copy number losses (Figure S1H). We
observed significant expression decreases of TCERG1, LARS,
YIPF5, and RBM27 in the 5q31.3-5q32 region (BH-adjusted Wil-
coxon p < 0.05) compared with cases retaining this region.
Verification of gene fusions confirmed 18 somatic and eight
germline fusion events (Table S2). Twenty-two of the 26 fusions
involved chromosome 22 (Figure S1J), with seven of these
fusions arising as a consequence of SMARCB1 deletion.
SPECC1L was a fusion partner in four of these seven cases.
Although these fusions may be passenger events, SPECC1L
alterations have been linked to phenotypes in human patients
(Saadi et al., 2011) and animal models (Gfrerer et al., 2014; Saadi
et al., 2011), which are consistent with disruption of neural crest
cell migration.
miRNA Analysis Reveals Tissue Types that Are Similar
to MRTs
MRTs are poorly differentiated cancers and the cell of origin is
unknown, complicating the selection of samples for comparative
analyses. miRNA profiles exhibit superior accuracy compared to
gene expression profiles in distinguishing tissue types of both
malignant and normal cells (Calin and Croce, 2006; Lu et al.,
2005; Rosenfeld et al., 2008) and have been used to identify tis-
sues of origin of poorly differentiated tumors (Ferracin et al.,
2011). We thus analyzed miRNA-seq data from 66 primary
MRTs (Table S1), detecting 535 mature miRNAs in MRT cases.
Using these, we performed unsupervised clustering analysis
to compare MRT miRNA profiles with TCGA and other miRNA
profiles from 11,819 cases representing 37 cancer types and
27 normal tissue types. MRT cases segregated into two groups396 Cancer Cell 29, 394–406, March 14, 2016 ª2016 Elsevier Inc.(Figures 2, S2, and Table S3): the larger group (n = 57) clustered
with normal cerebellum samples (MD_NORM, GBM_NORM) and
the TCGA category that contains paragangliomas and pheo-
chromocytomas (PCPG_TUM), which are cancers of neural crest
origin (Bolande, 1974). The smaller group (n = 9) clustered with
synovial sarcomas, which exhibit SWI/SNF dysregulation (Ka-
doch and Crabtree, 2013) and may be of neural origin (Ishibe
et al., 2008).
Candidate miRNA Target Genes Are Involved in Neuron
Development
We identified candidate miRNA targets, applying an approach
(Lim et al., 2015) we developed to identify targets with at least
one miRNA binding site predicted by both the miRanda (John
et al., 2004) and TargetScan (Friedman et al., 2009) algorithms,
and where the miRNA:mRNA pair showed anti-correlated
gene expression across 40 MRT samples (Table S1). Gene
ontology (GO) analysis (Huang et al., 2009a; 2009b) of targets
with the most significant candidate miRNA:mRNA interactions
(Spearman correlation rho < 0.65) indicated that candidate
miRNA targets included those involved in neuron development
and differentiation (e.g., VANGL2, ULK1, NGFR; Table S3),
compatible with the notion that these processes are targets of
miRNA-mediated dysregulation in MRTs. We also observed
that SMARCE1 was a putative target of miR-200a, compatible
with the notion that miRNA dysregulation in MRTs might influ-
ence expression of SWI/SNF complex members (Figure S3A).
EMT miRNAs Are Differentially Expressed between
miRNA Subgroups
Non-negative matrix factorization (NMF) consensus clustering
(Gaujoux and Seoighe, 2010) ofmiRNA-seq profiles (n = 66) iden-
tified an optimum of two subgroups (Figures 3, S3B, and S3C).
Seventeen miRNAs were overexpressed in miRNA subgroup 1,
and 12 were overexpressed in miRNA subgroup 2 (Figure 3;
log2FC > 1, false discovery rate [FDR] < 0.05). All five members
of the EMT-repressing miR-200 family (miR-200a, miR-200b,
miR-200c, miR-141, miR-429; Feng et al., 2014) were expressed
at lower levels in subgroup 1 compared to subgroup 2. The lower
expression levels of the miR-200 family in subgroup 1 are
compatible with the notion that EMT may be more active in sub-
group 1 relative to subgroup 2. Our observation is compatible
with previous reports of EMT regulation by SWI/SNF members
(Huang et al., 2008; Sa´nchez-Tillo´ et al., 2010).
RNA-seq Analysis Supports the Existence of MRT
Subgroups and Indicates Dysregulation of
Immunoglobulins and Developmental Genes
We used RNA-seq to analyze gene expression in 40 MRT cases
and three hESC lines (Table S1), the latter selected based on
studies indicating similarities between MRTs and hESCs in the
expression of stem cell associated-genes (Wilson et al., 2010)
and embryonic stem cell markers (Deisch et al., 2011; Venneti
et al., 2011). Informed by our miRNA analyses (Figure 2), we
obtained RNA-seq data from four fetal cerebellum samples to
use as additional normal comparators. 2,713 and 4,502 genes
were differentially expressed between MRT cases and hESC
lines and between MRT cases and fetal cerebellum samples,
respectively (FDR < 0.05, log2FC > 1; Table S4). Identification
Figure 2. Clustering of miRNA Expression Profiles from MRT and Other Tumor and Normal Tissue Types
MRT samples are represented individually, while non-MRT tumor and normal tissue types are represented by the medians of miRNA expression of all samples of
that type. Orange, MRT cases clustered with normal cerebellum samples (MD_NORM and GBM_NORM) and pheochromocytomas and paragangliomas
(PCPG_TUM); green, MRT cases clustered with synovial sarcomas (SARC). See also Figure S2 and Table S3.of genes common to both comparisons resulted in 398 genes
with increased abundance in MRTs versus both comparators
and 615 genes with decreased abundance in MRTs versus
both comparators. In MRTs, the most significantly overex-
pressed genes were linked to immune function (e.g., IGKC,
IGKJ5) and embryonic development (e.g.,MGP, LUM; Figure 4A;
Table S4), in agreement with previously reported associations of
SWI/SNF loss with immune (Agalioti et al., 2000; Cui et al., 2004;
Golding et al., 1999; Morshead et al., 2003) and developmental
(Li, 2002) dysregulation. The most significantly underexpressed
genes have been linked to aspects of embryonic development
(e.g., ZIC3, SOX3) and neuron function (e.g., GABRA3, CADPS;
Figure 4B and Table S4).
We used the top 25%most variably expressed protein-coding
genes (n = 3,179) to assess whether mRNA expression sup-
ported the existence of distinct subgroups. NMF consensus
clustering revealed an optimum of two subgroups (Figures 4C,
S4A, and S4B), a number generally supported by hierarchical
clustering and principal component analysis (Figures 4D and
4E). Organ site was significantly associated with subgroup 1(Fisher’s exact test p = 0.04), which included all six extra-renal
MRT cases from liver and soft tissues (Figure 4C and Table S1).
To address gene expression differences between subgroups,
we identified 880 genes differentially expressed (FDR < 0.05)
between subgroups 1 and 2 (Figure 4F and Table S4). In
subgroup 1, the 20 most significantly overexpressed genes
(log2FC > 2.5) were immunoglobulins, including those noted
above, and genes linked to BMP signaling (e.g., BMP4,
SOSTDC1) and differentiation (e.g., DLK1, MEOX2). In subgroup
2, the 20 most significantly overexpressed genes (log2FC > 6)
were linked to cell adhesion and migration (e.g., PCDH18,
SMOC2), WNT signaling (e.g.,WNT5A,HIC1), and differentiation
(TCF21,MEIS1). GO analysis indicated significant enrichment of
neural crest development and neural crest differentiation terms
(BH-adjusted p = 0.049; Table S4), consistent with the MRT
cell of origin deriving from the neural crest lineage (Blatt et al.,
1986; Fischer et al., 1989; Ota et al., 1993; Sugimoto et al.,
1999). Furthermore, the enriched categories spanned several
stages of neural crest development (Simo˜es-Costa and Bronner,
2015; Figure 4C). We also noted enhanced representation ofCancer Cell 29, 394–406, March 14, 2016 ª2016 Elsevier Inc. 397
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miRNA subgroup 1 miRNA subgroup 2 Figure 3. NMF Clustering of miRNA Expres-
sion Profiles
NMF consensus heatmap (top), clinical character-
istics of MRT cases in each group (middle), and
miRNAs that were differentially expressed between
subgroups 1 and 2 (n = 29; log2FC > 1, FDR < 0.05)
(bottom). Pan-cancer miRNA cluster, see Figure 2.
The labels, ‘‘Cerebellum’’ and ‘‘Synovial sarcoma’’
indicate MRT cases that clustered with normal
cerebellum and pheochromocytomas and para-
gangliomas, and with synovial sarcomas, respec-
tively. The silhouette width represents the robust-
ness of the clustering solution of two groups by
NMF. The yellow dashed line separates miRNA
subgroups. Each column represents a sample. See
also Figure S3 and Table S3.annotated tumor suppressors and oncogenes among differen-
tially expressed genes (hypergeometric p = 1.03 3 1039;
Table S4).
Our study notes the possibility of gene expression subgroups
in extra-cranial MRTs, although gene expression subgroups
were identified in AT/RT (Torchia et al., 2015). To assess whether
our MRT subgroups were more similar to AT/RT or to RTK, we
used data from Grupenmacher et al. (2013), which analyzed
gene expression differences between AT/RT and RTK. We
compared the genes differentially expressed between MRT sub-
groups with 29 genes reported by Grupenmacher et al. (2013)
as overexpressed in AT/RT relative to RTK (Table S4). Of these,
11 were differentially expressed between MRT subgroups 1 and
2 (FDR < 0.05). Ten of the 11 genes were overexpressed in
subgroup 1 (Table S4), including genes linked to neuronal differ-
entiation (e.g., BEX1, FAM5C/BRINP3; Coyle et al., 2011; Tera-
shima et al., 2010; Vilar et al., 2006) or neural crest differentiation
(e.g., ENC1; Rabada´n et al., 2013). Conversely, of the 92 genes
reported (Grupenmacher et al., 2013) as overexpressed in RTK
relative to AT/RT, 21 were differentially expressed between
subgroups 1 and 2, and all were overexpressed in subgroup 2
(one-sided Fisher’s exact p = 1.1933 1013; Table S4). These re-
sults are compatible with the notion thatMRT subgroup 1may be
more similar to AT/RT, andMRT subgroup 2may bemore similar
to RTK.398 Cancer Cell 29, 394–406, March 14, 2016 ª2016 Elsevier Inc.Extra-cranial MRTs Exhibit
Subgroups with Distinct
Methylation Profiles
Previous reports have linked SWI/SNF
complex action to CpG methylation (e.g.,
Kia et al., 2008). We thus sought to explore
the relationship between SMARCB1 loss
and genome-wide DNA methylation pat-
terns using whole-genome bisulfite se-
quencing analyses of 40 MRT cases, three
MRT cell lines, and three hESC lines
(TableS1).Weobtaineddata fromfourneu-
ral progenitor cell samples (NPCs; Road-
map Epigenomics Consortium, 2015) to
use as normal comparators. Unsupervised
clustering of promoter CpG island (CGI)
methylation revealed two MRT subgroups(Figure 5A). Subgroup A exhibited higher overall promoter CGI
methylation levels compared with subgroup B (Welch’s t test
p = 4.629 3 1016), a feature that was conserved outside CGIs
(Welch’s t test p = 2.2 3 1016; Figure 5B). MRT cell lines
had thehighest degreeofpromoterCGImethylationandclustered
with subgroup A. In contrast, subgroup B MRTs clustered with
hESCs and had lower overall methylation levels both within and
outside CGIs. Promoter-associated CGIs in bothMRT subgroups
were hypermethylated compared with NPCs and ESCs, while
non-CGI regions were hypomethylated (Figure 5B), consistent
with patterns generally observed in cancer epigenomes (Feinberg
and Vogelstein, 1983; Toyota et al., 1999). Correlatingmethylation
subgroups to clinical patient data revealed enrichment for pa-
tients >1 year of age in subgroup A (Figure 5A; one-sided Fisher’s
exact p = 0.0013). The only patient younger than 1 year in sub-
group A was 354 days old. Pathway analysis (Huang et al.,
2009a; 2009b) of promoters that gained methylation in subgroup
A showed significant enrichment in homeobox terms (BH-
adjusted Welch’s t test p < 0.05; Figure 5C).
Relative to hESCs, we noted a significant increase in the num-
ber of tumor suppressor gene (TSG) promoters that gained
methylation compared to TSG promoters that lost methylation
(one-sided Fisher’s exact p = 0.02041; Figure 5D and Table
S5). These included TSGs (annotated in the TSGene database;
Zhao et al., 2013) reported as methylated in other cancer types,
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Figure 4. Analysis of mRNA Expression Profiles
(A and B) Bar graphs show adjusted p values and numbers of genes (in brackets) mapped to top enriched GO terms for overexpressed genes (A) and under-
expressed genes (B) in MRTs compared with fetal cerebellum and hESCs (gray dashed line at p = 0.05).
(C) NMF consensus heatmap and clinical characteristics of 40 MRT samples (top); a heatmap showing overexpressed genes in subgroups 1 and 2, which were
enriched for pathways (*pathways with BH-corrected enrichment p < 0.05; pathways are assigned to genes as indicated by the black and gray bars on the right of
the heatmap) (middle); and mutations, differential expression, and differential CGI promoter methylation in genes that regulate various stages of neural crest
development (Simo˜es-Costa and Bronner, 2015), including neural plate border formation, neural crest specification and migration, and differentiation of neural
crest cells into various cell types including cardiac neural crest (Card), myoblast (Myo), and sympathetic neurons (SN) (bottom). Each column represents a
sample.
(D and E) Hierarchical clustering (D) and principal component analysis (E) of 40 MRT samples. Blue and red colors indicate samples in NMF-derived subgroups
1 and 2, respectively.
(legend continued on next page)
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including RASSF1 (Dammann et al., 2003), IRX1 (Guo et al.,
2010), TWIST2 (Thathia et al., 2012), DLEC1 (Gebhard et al.,
2006; Qiu et al., 2008; Wang et al., 2012; Ying et al., 2009; Zhang
et al., 2010), and TBX5 (Yu et al., 2010).
MRTs Have Decreased H3K27me3 at Homeobox Gene
Promoters
SMARCB1 loss has been associatedwith gains in global levels of
H3K27me3 in extra-cranial MRT and AT/RT models (Wilson
et al., 2010). We thus assessed whether promoter H3K27me3
density could discriminate MRT samples from normal neuronal,
progenitor, and kidney cell types.
To assess MRT promoter H3K27me3 density, we performed
H3K27me3 ChIP-seq analysis of 35 primary MRT samples,
three MRT cell lines, two hESC lines, and one normal kid-
ney sample (Figure S5 and Table S1). We also obtained
H3K27me3 ChIP-seq data from two normal fetal brain samples
and two NPC samples from the Roadmap Epigenomics Con-
sortium (2015) (Table S1). We defined gene promoters as
regions ±2 kb of transcription start sites and identified pro-
moters with differential H3K27me3 densities in MRT samples
compared with normal samples. Hierarchical clustering of the
200 promoters most differentially methylated between MRT
and normal comparators revealed three gene clusters. One
exhibited increased H3K27me3 density relative to normal
comparators (Figure 6A) while the other two clusters exhibited
decreased H3K27me3 density. Pathway analysis (Huang et al.,
2009a; 2009b) of the genes associated with the 42 promoters
with increased H3K27me3 density did not reveal a statistically
significant enrichment of any functional category. In contrast,
analysis of genes associated with the 158 promoters exhibiting
decreased H3K27me3 density revealed statistically significant
enrichment in homeobox, HOX, and homeodomain terms
(FDRs ranged from 4.17 3 1044 to 1.67 3 1037; Figure 6B
and Table S6). Other enriched terms were related to pattern
formation, morphogenesis, and organogenesis, and also ap-
peared to be driven primarily by homeobox genes. Enrichment
of terms related to DNA binding, transcription, and transcription
regulation was also noted (Table S6).
Consistent with the observation that homeobox genes had
differentially methylated promoters, H3K27me3 analyses sup-
ported the notion that epigenetic reprogramming of homeobox
genes may be associated with SMARCB1 loss. However,
despite nearly universal SMARCB1 loss, this reprogramming is
heterogeneous within our MRT cohort.
MRT-Specific Super-enhancers Are Found at HOX Gene
Clusters
Super-enhancers, defined by high regional H3K27ac density
compared with typical enhancers, are important regulatory en-
tities in cancer and are often associated with driver pathways
specific to the cancer type from which they were derived
(Hnisz et al., 2013). We performed H3K27ac ChIP-seq on ten
primary MRT samples, three MRT cell lines, and three(F) 880 genes differentially expressed between subgroup 1 and subgroup 2 (FDR
shades indicate overexpressed genes in subgroup 2. Lighter shades indicate gen
detected at a FDR threshold of 0.01. Labels indicate the 20 most differentially ex
See also Figure S4 and Table S4.
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samples (Table S1). In addition, we obtained ChIP-seq data
from one normal fetal brain sample from the Roadmap Epige-
nomics Consortium (2015) (Table S1) to use as a normal
comparator. We analyzed H3K27ac peaks to define enhancers
and ranked these based on the H3K27ac peak enrichment sig-
nals and their local density to identify super-enhancers (Fig-
ures 7A and S6) as described in previous studies (Hnisz
et al., 2013; Whyte et al., 2013). To reveal candidate active
regulatory regions unique to MRT, we identified super-
enhancers that were in R50% of MRT samples and that
were absent in normal fetal brain and hESCs. This yielded
136 MRT-specific super-enhancers associated with 197 genes
(Table S7). Analysis of these genes revealed enrichment of
terms associated with DNA binding, homeobox, and homeo-
protein (FDR < 0.0001; Figure 7B and Table S7). These enrich-
ments appeared to be driven by members of the HOXA,
HOXB, HOXC, HISTH1, and HISTH2 gene clusters. Super-
enhancers were also associated with FLT3LG and STAT3
(Bromberg et al., 1999; Lynch et al., 1997), both of which are
involved in the regulation of cellular differentiation (Laouar
et al., 2003) and self-renewal capacity in embryonic stem
and neural crest cells (Ying et al., 2003).
The MRT-specific super-enhancers blanketing the histone H2
gene cluster and the HOXC cluster (Figure 7C) were striking and
in the latter case included the regulatory RNAHOTAIR, providing
a possible explanation for the increase in HOTAIR expression
previously reported in AT/RT (Chakravadhanula et al., 2014)
that we also observed in MRTs versus normal comparators (Fig-
ure 7D). We also observed high expression of HOXC gene
members in MRTs compared with normal cell types (Figure 7E).
Enrichment of HOX gene clusters in super-enhancer regions
is consistent with our observation of loss of H3K27me3 at
these loci.
DISCUSSION
We present here a reference genomic landscape of extra-cranial
MRTs, and as a demonstration of their utility, use the data to
implicate genes and pathways in MRT biology. Although it was
clear that the dominant driver alteration in MRTs is SMARCB1
loss, our data indicate that the effects of SMARCB1 loss on tran-
scriptional regulation are not uniform across MRT cases.
Clustering of miRNA-seq data of MRTs with those from other
tumor and normal cell types revealed two subgroups. The
smaller subgroup clustered with synovial sarcomas, which
exhibit SWI/SNF dysregulation (Kadoch and Crabtree, 2013)
and may be of neural origin (Ishibe et al., 2008). The larger sub-
group clustered with normal cerebella, and pheochromocy-
tomas and paragangliomas, both of which are cancers of neural
crest origin (Bolande, 1974). Our results are thus compatible with
the notion that extra-cranial MRTs may be derived from neural
crest cells. This notion was further reinforced by our RNA-seq
analyses, which revealed the differential expression of genes< 0.05). Blue shades indicate overexpressed genes in subgroup 1, while red
es detected at a FDR threshold of 0.05, while the darker shades indicate genes
pressed genes in each subgroup.
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Figure 5. Analysis of DNA Methylation Profiles
(A) Correlation between unsupervised clustering of promoter CpG island (CGI) methylation levels and patient age at diagnosis (1,000 tests based on all promoter
CGIs; approximately unbiasedp=0.03). TheheatmapdisplayspromoterCGIswith at least 15%difference inmethylation (rowmeans) between the twosubgroups.
(B) Boxplots show the distribution of CpG methylation levels outside CGIs (left) and the average methylation levels within CGIs (right) for MRT cases in
subgroups A (n = 10) and B (n = 30), MRT cell lines (n = 3), NPCs (n = 4), and hESCs (n = 3). The box indicates the interquartile range (IQR), with the line within the
box indicating the median level. The lines below and above the box indicate values within 1.5 IQR from the first and the third quartile, respectively.
(C) Pathway analysis of genes with hypermethylated promoter CGIs in subgroup A compared to subgroup B (BH-adjusted p < 0.05). The bar graph shows
adjusted p values and numbers of genes (in brackets) mapped to top enriched terms from Swiss-Prot Protein Information Resource (SP), InterPro (I), protein
annotation from the Simple Modular Architecture Research Tool (SMART; SM), UniProt sequence annotation (UP), and biological processes and molecular
function from Gene Ontology (GO-B and GO-M, respectively; gray dashed line at p = 0.05).
(D) Heatmap shows tumor suppressor promoter CGIs with methylation gain in MRT subgroups compared with hESCs (BH-adjusted Welch’s t test p < 0.05).
See also Table S5.
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Figure 6. Comparison of Global H3K27me3 Marks between MRTs and SMARCB1-Intact Samples
(A) Clustering of H3K27me3 promoter density of MRTs and normal cell types. Note that case PAKLYZ that clustered with normal cell types expressed both
SMARCB1 and SMARCA4 (mRNA 48.8 and 37.7 RPKM, respectively).
(B) Pathway analysis of gene promoters with lower H3K27me3 levels in MRTs compared with normal samples. The bar graph shows the adjusted p values and
numbers of genes (in brackets) mapped to top enriched terms from InterPro (I) and biological processes fromGene Ontology (GO-B; gray dashed line at p = 0.05).
See also Figure S5 and Table S6.that regulate neural crest induction, neural differentiation, and
axon guidance.
Clustering of CGI promoter methylation revealed two sub-
groups with distinct methylation profiles that correlated with
age at diagnosis. The subgroup consisting primarily of patients
older than 1 year exhibited gain of methylation at CGI promoters,
particularly of homeobox genes and TSGs, which is consistent
with the notion that the impact of SMARCB1 loss on CGI methyl-
ation is heterogeneous.
The genome-wide profile of H3K27me3 density at gene pro-
moters distinguished MRTs from other SMARCB1-intact cell
types. Loss of H3K27me3 marks was observed at promoters
of homeobox genes, and MRT-specific super-enhancers were
detected at the HOXA, HOXB, and HOXC clusters, consistent
with the notion that epigenetic reprogramming may promote
expression of homeobox genes and contribute to dysregulated
developmental processes in MRTs.
Taken together, our observations are compatible with the
notion that the MRT cell of origin is related to neural crest cells,
and that the consequences ofSMARCB1 loss inMRT are hetero-
geneous at the epigenetic and gene expression levels.EXPERIMENTAL PROCEDURES
Tissue Samples and Cell Lines
Sixty-seven primary extra-cranial MRTs (58 from kidneys, seven from soft
tissues, and two from liver) and 40 matched normal (16 adjacent kidney and
24 peripheral blood) samples were obtained from patients registered on the
Children’s Oncology Group (COG) protocol. Included were pre-therapy tumor
and normal DNA from peripheral blood or kidney from rhabdoid tumors, regis-402 Cancer Cell 29, 394–406, March 14, 2016 ª2016 Elsevier Inc.tered on the National Wilms Tumor Study Group 5 or on COG AREN03B2
banked by the COG Biopathology Center with parental informed consent.
Studies were performed with the approval of the University of British
Columbia - British Columbia Cancer Agency Research Ethics Board (REB
number H09-02558). Three MRT cell lines (G401, KP-MRT-RY, and KP-
MRT-NS; Garvin et al., 1993; Katsumi et al., 2008; Sugimoto et al., 1999),
and three hESC lines (H7, H9, and H14; Thomson et al., 1998) were used in
our study. The complete sample names and other details are provided in Table
S1. Details of sequencing library construction are in given in the Supplemental
Information. Tumor contents were estimated using APOLLOH (median =
88.0%; Ha et al., 2012).
Whole-Genome, miRNA-Seq, RNA-Seq, DNA Methylation, and
ChIP-Seq Analyses
Details are provided in the Supplemental Information.
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dataMatrix/TARGET_DataMatrix.html.
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